REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced an agreement with FUJIFILM Diosynth Biotechnologies (FUJIFILM) for the manufacture of REGENXBIO’s lead product candidates, including RGX-314 and RGX-501, which will support late-stage clinical development and early commercialization. This partnership builds on the foundation of REGENXBIO’s internal manufacturing and process development capabilities.
{iframe}https://www.streetinsider.com/Corporate+News/Regenxbio+%28RGNX%29+Enters+Strategic+Partnership+with+FUJIFILM+Diosynth+Biotechnologies/13714263.html{/iframe}